Hang Seng Bio-Tech Index plunges 6% as biotech stocks rout

The Hang Seng Bio-Tech Index tumbled more than 6% in intraday trading on Thursday, July 17, as a broad selloff swept across Hong Kong-listed healthcare and biotechnology stocks, with several major names losing more than a tenth of their market value.

"The scale of today's decline suggests a catalyst-driven event rather than routine profit-taking, though the exact trigger remains unclear," said Kevin Ip, an analyst covering Hong Kong equities. "Traders are pointing to potential regulatory headwinds or sector-specific news that may have triggered stop-loss cascades."

Kangfang Bio (康方生物) led the decline, falling more than 11%, alongside 3S Pharma (三生制药) and MicroPort Robot (微创机器人), which each dropped over 11%. Insilico Medicine (英矽智能) slid more than 10%. The selloff was broad-based, with the biotech sub-index on track for its worst single-day performance in recent months.

The rout in biotech names comes amid heightened sensitivity in the Hong Kong healthcare sector, where valuations have been under pressure from regulatory uncertainty and shifting investor sentiment toward loss-making drug developers. The sharp intraday move raises the risk of margin calls and further forced selling, particularly in names with thin liquidity. Market participants are watching for any official statement or company disclosures that could clarify the catalyst behind the coordinated decline.

This article is for informational purposes only and does not constitute investment advice.